Additional file 2 of Lung cancer metabolomics: a pooled analysis in the Cancer Prevention Studies

Additional file 2: Table S1. Metabolites associated with lung cancer risk at P-value < 0.05 in the entire population. Table S2. Lipid-associated metabolic pathways components identified in lung cancer cases compared to controls. Table S3. Amino acids-associated metabolic pathways components identified in lung cancer cases compared to controls. Table S4. Metabolites associated with lung cancer risk at P-value < 0.05 in female stratum. Table S5. Metabolites associated with lung cancer risk at P-value < 0.05 in male stratum. Table S6. Metabolites associated with lung cancer risk at P-value < 0.05 in follow-up time ≤ 3 years stratum. Table S7. Metabolites associated with lung cancer risk at P-value < 0.05 in follow-up time > 3 years stratum. Table S8. Metabolites associated with lung cancer risk at P-value < 0.05 in never smokers stratum. Table S9. Metabolites associated with lung cancer risk at P-value < 0.05 in ever smokers stratum. Table S10. Metabolites associated with lung cancer risk at P-value < 0.05 in localized lung cancer stage stratum. Table S11. Metabolites associated with lung cancer risk at P-value < 0.05 in reginal lung cancer stage stratum. Table S12. Metabolites associated with lung cancer risk at P-value < 0.05 in distant lung cancer stage stratum. Table S13. Metabolites associated with lung cancer risk at P-value < 0.05 in squamous cell carcinoma stratum. Table S14. Metabolites associated with lung cancer risk at P-value < 0.05 in adenocarcinoma stratum.